Original Article

Preliminary Study on Hepatoprotective Effect and Mechanism of (-)-Epigallocatechin-3-gallate against Acetaminophen-induced Liver Injury in Rats

Yongxu Lin\textsuperscript{a1}, Juan Huang\textsuperscript{b1}, Tingfang Gao\textsuperscript{b}, Yuanzi Wu\textsuperscript{b}, Da Huang\textsuperscript{b}, Fen Yan\textsuperscript{b*}\textsuperscript{a} and Zuquan Weng\textsuperscript{b*}\textsuperscript{a}

\textsuperscript{a}Department of Basic Education, Fujian Normal University, Fuzhou 350116, China. \textsuperscript{b}College of Biological Science and Engineering, Fuzhou University, Fuzhou 350116, China.

* Corresponding authors:
E-mail: yanfen@fzu.edu.cn; wengzq@fzu.edu.cn

Abstract

Antipyretic acetaminophen (APAP) is a commonly used drug that generally associates with liver injury. (-)-Epigallocatechin-3-gallate (EGCG), an active polyphenol extracted from green tea, is extensively reported to have the potential to impact a variety of human diseases. However, few studies were reported regarding the protective effect of EGCG on APAP-induced liver injury and the mechanism is still unclear. In this study, in-vitro and in-vivo experiments were carried out to verify the hepatoprotective effect of EGCG against APAP-induced liver injury and explore the potential mechanism. Results indicated that EGCG effectively relieved the liver injury caused by APAP, as well as APAP-induced mitochondrial dysfunction. The protective role of EGCG was not only attributed to its antioxidant capacity; but also might be related to the protective effect on hepatic mitochondrial impairment; based on that, EGCG could improve the membrane potential and activities of the respiratory chain complexes in liver mitochondria. Our study casts a new light on the mechanism of EGCG’s hepatoprotective effect and suggests that EGCG has considerable potential in developing tonics for relieving APAP-induced liver injury.

Keywords: EGCG; APAP; Liver Injury; Mitochondria; ROS.

Introduction

Adverse drug reaction (ADR) is a potential complication of any pharmacotherapy, and drug-induced liver injury is one of the most frequent and serious ADRs since liver is the major target organ for drug metabolism (1-5). According to information statistics, more than 1100 currently available drugs can lead to liver injury (6-8). Hence, drug-induced liver injury has a considerable impact on human health and has become a non-negligible public health problem.

Antipyretic acetaminophen (APAP) is a commonly used antipyretic and analgesic drug. However, overdosage of APAP will induce acute liver failure due to its highly reactive intermediate \textit{N}-acetyl-\textit{p}-benzoquinone imine (NAPQI), mainly catalyzed by cytochrome P450 (CYP) 2E1 and 3A4 (9-11). NAPQI can react with the sulphydryl groups of glutathione (GSH), resulting in cellular GSH depletion and the formation of reactive oxygen species (ROS) in the liver (12, 13). Excessive ROS are positively correlated with mitochondrial impairment, which has long been considered as an important mechanism for drug or chemical-induced liver injury (14). In addition, NAPQI can covalently

\textsuperscript{1}These authors contributed equally to this work.

\textsuperscript{*} Corresponding authors:
E-mail: yanfen@fzu.edu.cn; wengzq@fzu.edu.cn
conjugate to proteins and produce NAPQI-protein adducts after GSH depletion, which will also cause serious hepatotoxicity since mitochondrial proteins can be one of the chief targets attacked by NAPQI (15, 16). Therefore, APAP-induced liver injury may be highly related to mitochondrial impairment caused by NAPQI.

Several studies have demonstrated that some natural products, such as (-)-Epigallocatechin-3-gallate (EGCG), may relieve APAP-induced liver injury, but the relative mechanism is not fully clear (17-20). EGCG is the major tea flavonoid with multifarious alleged pharmacological effects and is commonly used as an essential component of many functional foods, such as antioxidants and weight loss aides (21-26). Recently, the protective effect of EGCG on drug-induced liver injury has aroused great interest of researchers. Yang and co-workers discovered that EGCG profoundly influenced hepatic CYPs, probably resulting in changed pharmacokinetics and toxicity of drugs (27). Bradshaw and co-workers reported that EGCG treatment restored Alzheimer’s amyloid-induced decrease of mitochondrial respiratory rates, mitochondrial membrane potential, ROS production, and adenosine triphosphate (ATP) levels by 50~85% (28).

Despite many research projects focused on the EGCG’s protective effect on hepatic damage, only a few studies were related to its function to APAP-induced acute liver injury. Recently, Yin and co-workers (18) reported that EGCG significantly reduced APAP-induced liver injury in rats, possibly due to EGCG lowering the activities of CYP enzymes, such as CYP3A4 and CYP2E1 (29). However, there is a lack of information about the protective effect and potential mechanism of EGCG against APAP-induced hepatic mitochondrial impairment.

Herein, the effect of EGCG on APAP-induced liver injury and hepatic mitochondrial impairment was investigated by comparing hepatic biological parameters and mitochondrial functions when rats and isolated liver mitochondria with the treatment of APAP or both APAP and EGCG. This study may provide more information about the mechanism of EGCG’s protective effect on APAP-induced liver injury.

Experimental

Materials

APAP, nicotinamide adenine dinucleotide (NADH), antimycin A, ubiquinone 1, sodium succinate, rotenone, 2,6-dichloroindophenol sodium, phospho(enol)pyruvic acid monopotassium salt, lactate dehydrogenase (LDH), ATP and oligomycin A were obtained from Sigma-Aldrich (St. Louis, MO, USA). All other chemicals with analytical grade were purchased from Sinopharm Chemical Reagent Co., Ltd (Shanghai, China). EGCG (>98% pure) was provided by Shanghai Ronghe Pharmacy Co., Ltd. (China).

Animals

Male Sprague-Dawley (SD) rats (230-280 g, Shanghai Lingchang Biotechnology Co., Ltd. China) with one group of six were used for this study, and the experimental design consisted of eight groups. In four groups of them, the 100 mg/kg EGCG as daily dose was administered to rats by gavage for five consecutive days, and the control group was fed with normal saline. Subsequently, three groups with the treatment of EGCG and another three groups without the treatment of EGCG were administered with 250, 500 and 1000 mg/kg APAP, respectively, by intraperitoneal injection. After 8 h, all rats were killed by CO₂. Blood samples from the postcaval vein were collected into coded tubes containing anticoagulant EDTA and then were used for the extraction of plasma by centrifugation. The liver tissues were isolated and stored at -80 °C. Partly liver samples were fixed in 10% neutral buffered formalin and then processed histological assessment with H-E staining. All experimental protocols employed herein were approved by the Committee on the Care of Laboratory Animal Resources, College of Biological Science and Engineering, Fuzhou University.

Methods

Measurement of alanine aminotransferase (ALT) and LDH activity

ALT and LDH in plasma were measured by ALT assay kit (Beckman Co., Ltd, German) and LDH assay kit (Shanghai Shenneng Biotechnology Co., Ltd, China), respectively.
Measurement of MDA, SOD and GSH activity

The levels of oxidative stress-malondialdehyde (MDA) and biomarkers for antioxidant-superoxide dismutase (SOD) and GSH were measured using a commercially available kit (Nanjing Jiancheng Bioengineering Institute, Nanjing, China). In brief, partly liver of rats was homogenized in ice-PBS, then the samples were centrifuged at 3000 g for 10 min at 4°C. The supernatants were used for the measurement of MDA, SOD, and GSH activities according to the manufacturers’ instructions.

Isolation of rat hepatic mitochondria

Rat liver mitochondria were prepared as the description of the previous report with minor modification (30). After being washed by isolation buffer (70 mM sucrose, 190 mM mannitol, 20 mM HEPES, 0.2 mM EDTA, pH 7.5), the liver was homogenized using a 100 ml Dounce type homogenizer. Then the concentrations of mitochondrial proteins were determined by the Bradford kit of Bio-Rad (Hercules, CA, USA).

Treatment of isolated liver mitochondria from untreated rats

After liver mitochondria from untreated rats were isolated according to the methods mentioned above, mitochondrial preparations (1 mg/mL) were incubated with 0, 3.75, 7.5, 15, 30, 45, 60, and 100 μM EGCG at room temperature for 30 min. On the other hand, APAP was dissolved in DMSO and added to final concentrations of 0, 20, 40, 60, 80, 100 mM in mitochondria preparations. The final DMSO concentration was 5‰. Before it was treated with 60 mM APAP for 5min, the mitochondria were incubated with 30, 60 and 100 μM EGCG for 30 min prior to downstream experiments.

Detection of mitochondrial membrane potential (MMP)

The analysis of MMP in liver tissues was determined by the Sigma-Aldrich (St. Louis, MO, USA) JC-10 Assay Kit according to the kit’s instructional manual, and the excitation wavelength was 488 nm, and the emission wavelengths were 530 nm and 590 nm. The fluorescence intensity ratio between 590 nm and 530 nm was calculated to reflect changes in MMP. At the same time, the changes of the membrane potential of mitochondria dyed by JC-10 were observed by a confocal fluorescence microscope (CTR6500, Leica) as described previously (31).

Measurement of respiratory chain complexes (RCCs) activities

Mitochondria treated with EGCG and/or APAP were centrifuged and re-suspended in 25 mM potassium phosphate (pH 7.2) and subjected to three cycles of freezing-and-thawing. The liver mitochondria treated with EGCG and/or APAP in-vitro and administered with EGCG and APAP in-vivo were used for the measurement of RCC I–V activities. The method is carried out according to a reported protocol (32), except that a smaller reaction volume of 0.2 mL was used.

Statistical analysis

SPSS statistical package (SPSS, Chicago, USA) was used to perform statistical analysis. Effect of APAP exposure on LDH, ALT, MDA, SOD, GSH, complex I and complex III in rats was performed using one-way analysis of variance (ANOVA). Student’s t-test was applied for comparisons between averages of two samples. For the histopathological data, the significance of a decreased incidence of centrilobular hypertrophy and granuloma of livers in the APAP-treated groups pre-incubated with EGCG, when compared to the corresponding APAP-treated groups without incubation of EGCG, was evaluated by Fisher’s exact test. The minimal of level of significance chosen was $p < 0.05$.

Results

In vitro evaluation of the protective effect of EGCG on APAP-induced mitochondrial impairment

MMP of rat livers was evaluated by JC-10 assay (Figure S1A) and confocal microscopy (Figure 1B), and results of two methods showed that APAP could significantly result in the decrease of red/green ratio representing the depolarization of MMP. APAP-induced
depolarization of MMP might be recovered by EGCG (Figure S1B and Figure 1C), when mitochondria were pre-incubated with EGCG before the 60 mM APAP treatment.

In Figures 2A and 2C, we further observed that APAP exposure had significant effects on decreasing RCC I and III activities, but not in RCC II, IV and V (Data not shown). When pre-treated with EGCG prior to APAP, the RCC I and III activities loss caused by APAP were significantly ameliorated (Figures 2B and 2D).

In-vivo evaluation of the protective effect of EGCG on APAP-induced liver injury in rat

After being treated with or without EGCG (100 mg/kg) by gavage, all rats were exposed to a different dosage of APAP. Then the plasma ALT and LDH levels of SD rats were measured to evaluate the effect of EGCG on the liver injury caused by APAP. As summarized in Figure 3, no matter whether the rats were pre-treated with or without EGCG, their plasma ALT and LDH levels increased.
significantly after being injected APAP for 8 h, compared to the control group without APAP treatment. Furthermore, with an increase in the APAP dosage, the plasma ALT and LDH levels of both groups went up. However, the plasma ALT and LDH levels in the rats fed with EGCG were much lower than rats without EGCG treatment at the same APAP dosage, suggesting that the EGCG remarkably restored the liver injury caused by APAP.

Figure 4 demonstrated the pathological changes in the hepatic tissue of rats in the APAP, EGCG and EGCG + APAP groups. The statistical analysis of the histopathological findings in rat livers was summarized in Table 1. In accordance with the results of ALT and LDH, APAP significantly caused centrilobular hypertrophy and granuloma. The APAP-induced histopathological findings were significantly reduced by pre-treatment of EGCG.

Biomarkers for oxidative stress - MDA, and biomarkers for antioxidant - SOD and GSH in the liver of SD rats were measured. As shown in Figure 5A, MDA concentrations in the liver of SD rats without EGCG treatment increased remarkably after APAP injection. However, under the administration of the same APAP dosage, the groups with pre-treatment of EGCG have significantly lower concentrations of MDA than those of the groups without EGCG treatment. After APAP injection, evident reduction of SOD activities and GSH concentrations were observed in both groups with and without EGCG treatment, and the reduction was in a dosage-dependent manner (Figure 5B-C). However, the rats with EGCG treatment showed much higher SOD and GSH concentrations than those without EGCG treatment, indicating the administration of EGCG, significantly relieved the levels of oxidative stress. On the other side, there was no significant difference in GSH content among the two groups at the high dose of APAP.

Figure 2. Effect of APAP on RCC I and III and protective role of EGCG in-vitro.
The quantitative data are mean ± SD, n = 3. In A and C, *p < 0.05, compared to 5% DMSO; in B and D, *p < 0.05, compared to control, and #p < 0.05, compared to 60 mM APAP.
Table 1. Incidence of pathological changes in liver tissues of SD rats with/without EGCG pre-treatment after being injected APAP for 8 h.

| Histopathology | EGCG (mg/kg) | No. of Rat | Degrees of pathological changes |
|----------------|--------------|------------|---------------------------------|
|                | 0            | 250        | 500                             | 1000                           | Total (250+500+1000) |
| Centrilobular  | 0            | 6          | 3 2 1 0                         | 0 1 2 3*                       | 3 5 6 4*            |
| Hypertrophy    | 100          | 6          | 4 2 0 0                         | 3 2 1 0*                       | 1 3 2 0*            |
|                | 100          | 6          | 5 1 0 0                         | 4 1 1 0                        | 2 3 1 0            |
| Ganuloma       | 0            | 6          | 1 1 3 1*                        | 0 1 3 2*                       | 5 3 7 3*            |
|                | 100          | 6          | 2 3 1 0*                        |                                  | 1 1 5 1 0*          |

- none; ±: extremely slight; +: slight; ++: moderate. *p < 0.05, based on Fisher’s exact test, and significantly different from the corresponding group exposed to 0 mg/kg APAP; #p < 0.05, based on the Fisher’s exact test, and significantly different from the corresponding group exposed to 0 mg/kg EGCG.

Figure 3. (A) ALT and (B) LDH levels in the plasma of SD rats with/without EGCG pre-treatment after being injected APAP for 8 h. Values represent the mean ± SD. *p < 0.05, based on student’s t-test.

Figure 4. Photomicrophs (original magnification × 200) of H&E-stained livers in rats. (A) control; (B) EGCG-only; (C) APAP-only; (D) EGCG+APAP.
Hepatoprotective effect of (-)-Epigallocatechin-3-gallate

APAP (1000 mg/kg), which suggested that 100 mg/kg EGCG has less effect on 1000 mg/kg APAP-induced GSH depletion.

The activities of RCCs in liver mitochondria of rats treated with or without EGCG were measured to investigate the possible hepatic mitochondrial impairment caused by APAP. As demonstrated in Figure 6, both RCC I and III activities reduced with the increase of dosage of APAP, indicating hepatic mitochondrial

Figure 5. (A) MDA, (B) SOD and (C) GSH levels in the liver of SD rats with/without EGCG pre-treatment after being injected APAP for 8 h. Values represent the mean ± SD. *p < 0.05, based on student’s t-test.

Figure 6. Activities of RCC (A) I and (B) III in liver mitochondria of SD rats with/without EGCG treatment after being injected APAP for 8 h. Values represent the mean ± SD. *p < 0.05, based on student’s t-test.
injury caused by APAP. However, higher RCC I and III activities were observed in liver mitochondria of rats with EGCG treatment, manifesting that EGCG administration could recover the lower activities of mitochondrial RCCs induced by APAP.

The liver mitochondria of rats were administrated EGCG with different concentrations. Then the activities of all RCCs in liver mitochondria were determined and results were shown in Figure S3. In the range of 0 to 100 μM EGCG, data revealed hardly any significant influence on activities of all RCCs. These results turned out that only treated with EGCG did not affect the activities of RCCs in liver mitochondria remarkably.

Discussion

Pathological changes in the liver and increases in serum ALT and LDH levels are the main characteristics of liver damage. The results of our study showed that APAP could significantly increase the damage degrees of centrilobular hypertrophy and granuloma in rat livers, and the levels of serum ALT and LDH in a dose-dependent manner, while pre-treatment of EGCG significantly decreased the elevation, demonstrating that EGCG is effective in alleviating hepatic injury caused by APAP.

In addition to lower ALT and LDH levels, we also observed that the higher level of MDA in the liver of rats caused by the injection of APAP was reduced by pre-treating with EGCG. Moreover, EGCG could also reduce the depletion of GSH and SOD caused by APAP. It has been reported that APAP toxicity mediated by the reactive metabolite NAPQI, which was catalyzed by CYPs, mainly are CYP2E1 and 3A4 (33, 34). The previous study proved that EGCG could covalently bind to cysteinyl thiol groups in protein (35), and the following researches indicated that EGCG could reduce the formation of NAPQI, due to that the ability of EGCG to covalently bind to various CYPs and inhibit the activities of CYP2E1 and 3A4 (18, 29 and 36).

It should be noted that a small amount of NAPQI will not cause liver toxicity because it will be detoxified by combination with GSH, which is the original detoxifying substance in the liver. However, NAPQI will exhaust GSH by the reaction of GSH with excessive NAPQI after an APAP overdose (37), further leading to a lot of ROS accumulation in the body and eventually resulting in a higher level of MDA and a lower level of SOD (38). According to our results, EGCG administration followed by APAP markedly reduced MDA production and increased the levels of GSH and SOD, which exhibited that EGCG had a good antioxidant capacity, in accordance with the previous report (24).

Many studies provided convincing evidence that mitochondrial ROS played a critical role in APAP-induced liver injury (14, 39 and 40). Besides the metabolism of APAP and accumulation of its toxic metabolite in the liver, the inhibitory effect of APAP and/or its metabolite on RCCs activities in liver mitochondria was another cause of liver injury (41-43). After GSH depletion, NAPQI would bind to the thiol side chains of cysteine residues in mitochondrial proteins, which might result in the inactivation of mitochondrial functions (44-48). And mitochondrial dysfunctions caused the generation of a large amount of ROS (49). Excessive ROS, in turn, would impair mitochondria, thus forming a vicious circle and finally led to hepatic impairment. Previously, Salminen and co-workers reported that green tea extract with 48.4% EGCG essentially eliminated the production of NAPQI covalently binding to proteins (50). The findings suggested that EGCG could prevent NAPQI from binding to mitochondrial proteins by its direct reaction with NAPQI, similar to the reaction of NAPQI with GSH. In our results, in-vitro study illustrated that EGCG pre-incubation could prevent APAP-induced mitochondrial damage, including the depolarization of MMP and decrease of RCC I and III, and the later results were further confirmed by the data obtained from in vivo study. These findings taken together showed that EGCG plays a protective role on APAP-induced liver injury by maintaining mitochondrial integrity. Therefore, we deduced that EGCG either scavenged the excessive ROS or prevented the formation of NAPQI and NAPQI-protein adducts, thereby protecting the integrity of mitochondrial function. Further basic studies are needed to
verify this viewpoint. Miteshkumar and co-workers ever reported that N-acetylcysteine, hypotaurine and taurine could equally attenuate the hepatic injury (17). However, they are all drugs that may be associated with side effects, and in comparison to them, natural product EGCG is much safer. Our experiment results also showed that EGCG did not significantly affect the activities of RCCs, even at a very high EGCG dosage of 100 μM. In fact, the average maximum plasma concentration (C_{max}) of EGCG was 0.3-7.4 μM, some individuals had as high as 13.2 μM EGCG in the blood (51, 52), and this range concentrations of EGCG could not affect the RCCs activities. Therefore, EGCG is a promising candidate as tonics for relieving liver injury induced by APAP.

**Conclusion**

In conclusion, our study demonstrated that EGCG could effectively restore the APAP-induced liver injury by its antioxidant capacity and recovering the lower activities of RCCs in liver mitochondria caused by APAP. It is the first time to propose that the protective effect of EGCG on APAP-induced liver injury is due to EGCG can alleviate the hepatic mitochondrial impairment, probably via eliminating ROS and reducing the reactive intermediate (NAPQI) of APAP and NAPQI-protein adducts. We believe this study casts a new light on the mechanism of EGCG’s hepatoprotective effect and suggests that EGCG has considerable potential in developing tonics for treating APAP-induced liver injury.

**Acknowledgments**

This work was supported by Funds of Industry and School and Research Project in Fuzhou Science and Technology Bureau (2018-G-49), Funds of Joint Plan for Health Education in Fujian (WKJ2016-2-25), and the National Natural Science Foundation of China (81971837).

**References**

(1) Liu M, Wu Y, Chen Y, Sun J, Zhao Z, Chen XW, Matheny ME and Xu H. Large-scale prediction of adverse drug reactions using chemical, biological, and phenotypic properties of drugs. *J. Am. Med. Inform. Assoc.* (2012) 19: e28-35.

(2) Barbaud A, Collet E, Milpied B, Assier H, Staumont D, Avenel-Audran M, Grange A, Amarger S, Girardin P, Guinneck MF, Truchetet F, Lasek A and Waton J. A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions. *Br. J. Dermatol.* (2013) 168: 555-62.

(3) Iorga A, Dara L and Kaplowitz N. Drug-induced liver injury: cascade of events leading to cell death, apoptosis or necrosis. *Int. J. Mol. Sci.* (2017) 18.

(4) Kleiner DE. Drug-induced Liver Injury: The Hepatic Pathologist’s Approach. *Gastroenterol Clin. North Am.* (2017) 46: 273-96.

(5) Kullak-Ublick GA, Andrade RJ, Merz M, End P, Benesic A, Gerbes AL and Aithal GP. Drug-induced liver injury: recent advances in diagnosis and risk assessment. *Gut.* (2017) 66: 1154-64.

(6) Luo G, Shen Y, Yang L, Lu A and Xiang Z. A review of drug-induced liver injury databases. *Arch. Toxicol.* (2017) 91: 3039-49.

(7) Lee SJ, Lee YJ and Park KK. The pathogenesis of drug-induced liver injury. *Expert Rev. Gastroenterol. Hepatol.* (2016) 10: 1175-85.

(8) Stirnimann G, Kessebohm K and Lauterburg B. Liver injury caused by drugs: an update. *Swiss Med. Wkly.* (2010) 140: w13080.

(9) Temple AR, Temple BR and Kuffner EK. Dosing and antipyretic efficacy of oral acetaminophen in children. *Clin. Ther.* (2013) 35: 1361-75.e1-45.

(10) Manimaran A, Sarkar SN and Sankar P. Toxicodynamics of subacute co-exposure to groundwater contaminant arsenic and analgesic-antipyretic drug acetaminophen in rats. *Ecotoxicol. Environ. Saf.* (2010) 73: 94-100.

(11) Vale JA and Proudfoot AT. Paracetamol (acetaminophen) poisoning. *Vet. Hum. Toxicol.* (1995) 346: 547-52.

(12) Khayyat A, Tobwala S, Hart M and Ercal N. N-acetylcysteine amide, a promising antidote for acetaminophen toxicity. *Toxicol. Lett.* (2016) 241: 133-42.

(13) Santoh M, Sanoh S, Ohtsuki Y, Ejiri Y, Kotake Y and Ohta S. Acetaminophen analog N-acetyl-m-aminophenol, but not its reactive metabolite, N-acetyl-p-benzoquinone imine induces CYP3A activity via inhibition of protein degradation. *Biochem. Biophys. Res. Commun.* (2017) 486: 639-44.

(14) Jaeschke H, McGill MR and Ramachandran A. Oxidant stress, mitochondria, and cell death mechanisms in drug-induced liver injury: lessons
learned from acetaminophen hepatotoxicity. Drug Metab. Rev. (2012) 44: 88-106.

(15) Abiko Y, Ishii I, Kamata S, Tsuchiya Y, Watanabe Y, Ihara H, Akaikie T and Kumagai Y. Formation of sulfur adducts of N-acetyl-p-benzoquinonemine, an electrophilic metabolite of acetaminophen in vivo: participation of reactive persulfides. Chem. Res. Toxicol. (2015) 28: 1796-802.

(16) Koen YM, Liu K, Shinogle H, Williams TD and Hanzlik RP. Comparative toxicity and metabolism of N-acetyl homologues of acetaminophen and its isomer 3'-hydroxyacetanilide. Chem. Res. Toxicol. (2016) 29: 1857-64.

(17) Acharya M and Lau-Cam CA. Comparison of the protective actions of N-acetylcyesteine, hypotaurine and taurine against acetaminophen-induced hepatotoxicity in the rat. J. Biomed. Sci. (2010) 17 Suppl 1: S35.

(18) Yao HT, Yang YC, Chang CH, Yang HT and Yin MC. Protective effects of (-)-epigallocatechin-3-gallate against acetaminophen-induced liver injury in rats. Biomedicine (Taipei) (2015) 5: 15.

(19) Nguyen NU and Stamper BD. Polyphenols reported to shift APAP-induced changes in MAPK signaling and toxicity outcomes. Chem. Biol. Interact. (2017) 277: 129-36.

(20) Xu XY, Hu JN, Liu Z, Zhang R, He YF, Hou W, Wang ZQ, Yang G and Li W. Saponins (Ginsenosides) from the leaves of Panax quinquefolius ameliorated hepatotoxicity in mice. J. Agric. Food Chem. (2017) 65: 3684-92.

(21) Zhang L, Wei Y and Zhang J. Novel mechanisms of anticancer activities of green tea component epigallocatechin-3-gallate. Anticancer Agents Med. Chem. (2014) 14: 779-86.

(22) Suzuki T, Pervin M, Goto S, Isemura M and Nakamura Y. Beneficial effects of tea and the green tea catechin epigallocatechin-3-gallate on obesity. Molecules. (2016) 21.

(23) Singh NA, Mandal AK and Khan ZA. Potential neuroprotective properties of epigallocatechin-3-gallate (EGCG). Nutr. J. (2016) 15: 60.

(24) Kim HS, Quon MJ and Kim JA. New insights into the mechanisms of polyphenols beyond antioxidant properties; lessons from the green tea polyphenol, epigallocatechin 3-gallate. Redox Biol. (2014) 2: 187-95.

(25) Williamson G, Dionisi F and Renouf M. Flavanols from green tea and phenolic acids from coffee: critical quantitative evaluation of the pharmacokinetic data in humans after consumption of single doses of beverages. Mol. Nutr. Food Res. (2011) 55: 864-73.

(26) Singh T and Katiyar SK. Green tea catechins reduce invasive potential of human melanoma cells by targeting COX-2, PGE2 receptors and epithelial-to-mesenchymal transition. PLoS One. (2011) 6: e25224.

(27) Yang CS and Pan E. The effects of green tea polyphenols on drug metabolism. Expert Opin. Drug Metab. Toxicol. (2012) 8: 677-89.

(28) Dragicevic N, Smith A, Lin X, Yuan F, Copes N, Delic V, Tan J, Cao C, Shyle RD and Bradshaw PC. Green tea epigallocatechin-3-gallate (EGCG) and other flavonoids reduce alzheimer’s amyloid-induced mitochondrial dysfunction. J. Alzheimers Dis. (2011) 26: 507-21.

(29) Chen X, Sun CK, Han GZ, Peng JY, Li Y, Liu YX, Lv YY, Liu KX, Zhou Q and Sun HJ. Protective effect of tea polyphenols against paracetamol-induced hepatotoxicity in mice is significantly correlated with cytochrome P450 suppression. World J. Gastroenterol. (2009) 15: 1829-35.

(30) Waldmeier PC, Feldtrauer JJ, Qian T and Lemasters JJ. Inhibition of the mitochondrial permeability transition by the nonimmunosuppressive cyclosporin derivative NIM811. Mol. Pharmacol. (2002) 62: 22-9.

(31) Davidson SM, Yellon D and Duchen MR. Assessing mitochondrial potential, calcium, and redox state in isolated mammalian cells using confocal microscopy. Methods Mol. Biol. (2007) 372: 421-30.

(32) Lu Y, Zhang C, Chen YH, Wang H, Zhang ZH, Chen X and Xu DX. Immature mice are more susceptible than adult mice to acetaminophen-induced acute liver injury. Sci. Rep. (2017) 7: 42736.

(33) Li J, Kaneko T, Wang Y, Qin LQ, Wang PY and Sato A. Troglitazone enhances the hepatotoxicity of acetaminophen by inducing CYP3A in rats. Toxicology. (2002) 176: 91-100.

(34) Yamaura K, Shimada M, Nakayama N and Ueno K. Protective effects of goldenseal (Hydrastis canadensis L.) on acetaminophen-induced hepatotoxicity through inhibition of CYP2E1 in rats. Pharmacognosy Res. (2011) 3: 250-5.

(35) Ishii T, Mori T, Tanaka T, Mizuno D, Yamaji R, Kumazawa S, Nakayama T and Akagawa M. Covalent modification of proteins by green tea polyphenol (-)-epigallocatechin-3-gallate through autoxidation. Free Radic. Biol. Med. (2008) 45: 1384-94.

(36) Weng Z, Greenhaw J, Salminen WF and Shi Q. Mechanisms for epigallocatechin gallate induced inhibition of drug metabolizing enzymes in rat liver microsomes. Toxicol. Lett. (2012) 214: 328-38.

(37) McGill MR and Jaeschke H. Metabolism and
Hepatoprotective effect of (-)-Epigallocatechin-3-gallate
disposition of acetaminophen: recent advances in relation to hepatotoxicity and diagnosis. Pharmac. Res. (2013) 30: 2174-87.
(38) Weng Z, Zhou P, Salminen WF, Yang X, Harrill AH, Cao Z, Mattes WB, Mendrick DL and Shi Q. Green tea epigallocatechin gallate binds to and inhibits respiratory complexes in swelling but not normal rat hepatic mitochondria. Biochem. Biophys. Res. Commun. (2014) 443: 1097-104.
(39) James LP, McCullough SS, Knight TR, Jaeschke H and Hinson JA. Acetaminophen toxicity in mice lacking NADPH oxidase activity: role of peroxynitrite formation and mitochondrial oxidant stress. Free Radic. Res. (2003) 37: 1289-97.
(40) Saito C, Zwingmann C and Jaeschke H. Novel mechanisms of protection against acetaminophen hepatotoxicity in mice by glutathione and N-acetylcysteine. Hepatology. (2010) 51: 246-54.
(41) Wang H, Shao Y, Zhang S, Xie A, Ye Y, Shi L, Jin L, Pan X, Lin Z, Li X and Yang S. CXCL16 deficiency attenuates acetaminophen-induced hepatotoxicity through decreasing hepatic oxidative stress and inflammation in mice. Acta Biochim. Biophys. Sin. (Shanghai) (2017) 49: 541-9.
(42) Du K, Ramachandran A, McGill MR, Mansouri A, Asselah T, Farhood A, Woolbright BL, Ding WX and Jaeschke H. Induction of mitochondrial biogenesis protects against acetaminophen hepatotoxicity. Food Chem. Toxicol. (2017) 108: 339-50.
(43) He Y, Feng D, Li M, Gao Y, Ramirez T, Cao H, Kim SJ, Yang Y, Cai Y, Ju C, Wang H, Li J and Gao B. Hepatic mitochondrial DNA/Toll-like receptor 9/ MicroRNA-223 forms a negative feedback loop to limit neutrophil overactivation and acetaminophen hepatotoxicity in mice. Hepatology. (2017) 66: 220-34.
(44) Zhang T, Zhang Q, Guo J, Yuan H, Peng H, Cui L, Yin J, Zhang L, Zhao J, Li J, White A, Carmichael PL, Westmoreland C and Peng S. Non-cytotoxic concentrations of acetaminophen induced mitochondrial biogenesis and antioxidant response in HepG2 cells. Environ. Toxicol. Pharmacol. (2016) 46: 71-9.
(45) Liu J, Tang Y, Feng Z, Liu J, Liu J and Long J. (-)-Epigallocatechin-3-gallate attenuated myocardial mitochondrial dysfunction and autophagy in diabetic Goto-Kakizaki rats. Free Radic. Res. (2014) 48: 898-906.
(46) Du K, Farhood A and Jaeschke H. Mitochondria-targeted antioxidant Mito-Tempo protects against acetaminophen hepatotoxicity. (2017) 91: 761-73.
(47) Matthews AM, Hinson JA, Roberts DW and Pumford NR. Comparison of covalent binding of acetaminophen and the regioisomer 3'-hydroxyacetanilide to mouse liver protein. Toxicol. Lett. (1997) 90: 77-82.
(48) Leeming MG, Gamon LF, Wille U, Donald WA and O’Hair RA. What are the potential sites of protein arylation by N-acetyl-p-benzoquinone imine (NAPQI)? Chem. Res. Toxicol. (2015) 28: 2224-33.
(49) Hanawa N, Shinohara M, Saberi B, Gaarde WA, Han D and Kaplowitz N. Role of JNK translocation to mitochondria leading to inhibition of mitochondria bioenergetics in acetaminophen-induced liver injury. J. Biol. Chem. (2008) 283: 13565-77.
(50) Salminen WF, Yang X, Shi Q, Greenhaw J, Davis K and Ali AA. Green tea extract can potentiate acetaminophen-induced hepatotoxicity in mice. Food Chem. Toxicol. (2012) 50: 1439-46.
(51) Ullmann U, Haller J, Decourt JP, Girault N, Girault J, Richard-Caudron AS, Pineau B and Weber P. A single ascending dose study of epigallocatechin gallate in healthy volunteers. J. Int. Med. Res. (2003) 31: 88-101.
(52) Chow HH, Hakim IA, Vining DR, Crowell JA, Ranger-Moore J, Chew WM, Celaya CA, Rodney SR, Har Y and Alberts DS. Effects of dosing condition on the oral bioavailability of green tea catechins after single-dose administration of Polyphenon E in healthy individuals. Clin. Cancer Res. (2005) 11: 4627-33.

This article is available online at http://www.ijpr.ir